Climb Bio (CLYM)

• Market cap: $488M
• 1 day: -3.12%
• 5 days: 27.22%
• 1 month: 39.65%
• 3 months: 278.31%
• 6 months: 212.23%
• Year to date: 90.67%
• 1 year: 414.39%
• 5 years: -55.03%
• 10 years: -55.03%
• Sector: Healthcare
• Industry: Biotechnology

About: Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. its product candidate, budoprutug, is an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has the potential to treat a broad range of B-cell-mediated diseases.

Employees: 18